These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37956143)

  • 1. Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia.
    Cameron JK; Chandrasiri U; Millar J; Aitken JF; Cramb S; Dunn J; Frydenberg M; Rashid P; Mengersen K; Chambers SK; Baade PD; Smith DP
    PLoS One; 2023; 18(11):e0293954. PubMed ID: 37956143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
    Coory MD; Baade PD
    Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience.
    Guedea F; Ferrer M; Pera J; Aguiló F; Boladeras A; Suárez JF; Cunillera O; Ferrer F; Pardo Y; Martínez E; Ventura M
    Clin Transl Oncol; 2009 Jul; 11(7):470-8. PubMed ID: 19574206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
    Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
    J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
    Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
    BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
    Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
    BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
    Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
    J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment.
    Liberman D; Jarosek S; Virnig BA; Chu H; Elliott SP
    J Urol; 2016 May; 195(5):1459-1463. PubMed ID: 26682759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower urinary tract symptoms of prostate cancer patients undergoing treatments over eight-month follow-up.
    Li HC; Chen KM; Lin YH; Chen TB
    J Clin Nurs; 2015 Aug; 24(15-16):2239-46. PubMed ID: 25950902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.
    Sureda A; Fumadó L; Ferrer M; Garín O; Bonet X; Castells M; Mir MC; Abascal JM; Vigués F; Cecchini L; Suárez JF
    Health Qual Life Outcomes; 2019 Jan; 17(1):11. PubMed ID: 30642340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
    Pompe RS; Smith A; Bandini M; Marchioni M; Martel T; Preisser F; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Shariat SF; Tilki D; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):71-77. PubMed ID: 29339806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.